Abstract 57P
Background
The formation of distant metastases is the deadliest phase of cancer progression. Nevertheless, it is a very inefficient process. Chances of a tumor cell surviving the metastatic process depend on its ability to communicate with the surrounding environment. We hypothesize that metastasis organotropism can be partially explained by the intercellular communication established between cancer cells and other cells in the organ microenvironment.
Methods
Network biology tools are well suited for studying complex diseases such as cancer. Using this computational approach we looked at the complex interplay between proteins and pathways affected in metastasis and identified new metastasis-associated proteins. We built networks of tissue-specific intercellular protein-protein interactions between pairs of primary tumor location and metastasis tissues. Using these networks we identified interactions significantly more frequent in organotropism tissue pairs (primary tumor and metastasis organ) that potentially influence the success of metastasis in specific organs.
Results
Overall, we identified 607 proteins involved in 1095 metastasis-associated interactions. Of these, 881 interactions were positively associated with metastasis, meaning that these interactions occur more frequently in organotropism tissue-pairs than in other tissue pairs. Of the 607 proteins found, 222 are already targeted by known drugs and 53 are targeted by drugs that are not used in cancer treatment.
Conclusions
Cell-cell communication is of paramount importance for the development of metastasis. Experimental studies of the non-oncological drugs targeting the 53 identified proteins are needed to select the most promising candidates to test in drug repurposing clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Presenter: MIGUEL GALINDO CAMPOS
Session: Poster session 09
15P - CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Presenter: Luisa Chocarro
Session: Poster session 09
16P - Terminally exhausted CD8+ T cells and increased immunosuppressive soluble factors in malignant ascites of patients with gastric cancer with peritoneal metastasis
Presenter: Hye Sook Han
Session: Poster session 09
17P - Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade
Presenter: Robert Watson
Session: Poster session 09
18P - Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Presenter: Alessandro Cavaliere
Session: Poster session 09
19P - Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy
Presenter: Yanelys Morera
Session: Poster session 09
20P - The essential role of DNA repair in the pharmacological activities of AST-3424
Presenter: Fanying Meng
Session: Poster session 09
21P - Implications of KMT2C knockdown for DNA damage repair in breast cancer
Presenter: Philip Bredin
Session: Poster session 09
22P - Clinical significance of DNA damage response mutations in early stage NSCLC
Presenter: Haoran Zhang
Session: Poster session 09
23P - PMC-309: A highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive
Presenter: Cheon Ho Park
Session: Poster session 09